Growth stimulating antibody, as another predisposing factor of Graves' disease (GD): analysis using monoclonal TSH receptor antibodies derived from patients with GD.
Ihara Y, Kanda Y, Seo M, Watanabe Y, Akamizu T, Tanaka Y.SourceDepartment of General Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan.
Endocrine journal.Endocr J.2012 Jul 31;59(7):571-7. Epub 2012 May 18.
TSH receptor antibody (TRAb) is clinically classified into thyroid stimulating antibody (TSAb) and thyroid-stimulation blocking antibody (TSBAb). Although the former is considered to cause Graves' disease (GD), its activity does not necessarily reflect hormone production and goiter size. Moreover,
A TSHr-LH/CGr Chimera that Measures Functional TSAb in Graves' Disease.
Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Fiore E, Bucci I, Chamblin T, Vitti P, Monaco F, Napolitano G.SourceUnit of Endocrinology, Department of Medicine and Sciences of Aging, University "G. D'Annunzio" and Aging Research Center, Centro Scienze dell'Invecchiamento, "Gabriele D'Annunzio" University Foundation, 66013 Chieti-Pescara, Italy. gnapol@unich.it.
The Journal of clinical endocrinology and metabolism.J Clin Endocrinol Metab.2012 Jul;97(7):E1106-15. Epub 2012 Apr 10.
Context: Stimulating thyrotropin receptor (TSHr) autoantibodies (TSAb) are the cause of hyperthyroidism in Graves' disease. In a patient's serum, TSAb can coexist with antagonist TSHr autoantibodies that block TSAb stimulatory activity (TSBAb); both can vary in amount and time. Objective: The objec